CAR T-cell Therapy Market
Description
Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2026 - 2033
CAR T-cell Therapy Market Summary
The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, growing at a CAGR of 18.06% from 2026 to 2033. Market growth is driven by rising cancer prevalence, adoption of personalized cell therapies, advances in gene editing, and supportive regulations.
Rising Cancer Burden
The rising prevalence of cancer, especially blood cancers like leukemia, lymphoma, and multiple myeloma, is driving the CAR T-cell therapy industry. Traditional treatments often fail to achieve long-term remission, while CAR T-cell therapies, which engineer a patient’s T-cells to target cancer, offer higher efficacy and durable responses. Increasing global cancer incidence is boosting demand for these advanced, personalized treatments.
Limited options for aggressive or treatment-resistant blood cancers support CAR T-cell market growth. These therapies address critical unmet needs, and rising awareness among healthcare professionals and patients is driving adoption. Expanding clinical trials into other cancers and solid tumors is expected to increase demand further, making CAR T-cell therapy a central focus in oncology.
Global CAR T-cell Therapy Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CAR T-cell therapy market report based on product, disease indication, end use, and region:
CAR T-cell Therapy Market Summary
The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, growing at a CAGR of 18.06% from 2026 to 2033. Market growth is driven by rising cancer prevalence, adoption of personalized cell therapies, advances in gene editing, and supportive regulations.
Rising Cancer Burden
The rising prevalence of cancer, especially blood cancers like leukemia, lymphoma, and multiple myeloma, is driving the CAR T-cell therapy industry. Traditional treatments often fail to achieve long-term remission, while CAR T-cell therapies, which engineer a patient’s T-cells to target cancer, offer higher efficacy and durable responses. Increasing global cancer incidence is boosting demand for these advanced, personalized treatments.
Limited options for aggressive or treatment-resistant blood cancers support CAR T-cell market growth. These therapies address critical unmet needs, and rising awareness among healthcare professionals and patients is driving adoption. Expanding clinical trials into other cancers and solid tumors is expected to increase demand further, making CAR T-cell therapy a central focus in oncology.
Global CAR T-cell Therapy Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CAR T-cell therapy market report based on product, disease indication, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Abecma (idecabtagene vicleucel)
- Breyanzi (lisocabtagene maraleucel)
- Carvykti (ciltacabtagene autoleucel)
- Kymriah (tisagenlecleucel)
- Tecartus (brexucabtagene autoleucel)
- Yescarta (axicabtagene ciloleucel)
- Others
- Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Leukemia
- Lymphoma
- Multiple Myeloma
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Cancer Treatment Centers
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- Rest of World
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Product Segment
- 1.1.1.2. Disease Indication Segment
- 1.1.1.3. End Use Segment
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objective
- 1.4.1. Objective 1
- 1.4.2. Objective2
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR’s Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis:
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Secondary Sources
- 1.11. List of Abbreviations
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising cancer burden
- 3.2.1.2. Personalized treatment advantage
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Regulatory complexity
- 3.3. Industry Analysis Tools
- 3.3.1. Porter’s Five Forces Analysis
- 3.3.2. PESTEL Analysis
- Chapter 4. Product Business Analysis
- 4.1. Product Segment Dashboard
- 4.2. CAR T-cell Therapy Market: Product Movement Analysis
- 4.3. Abecma (idecabtagene vicleucel)
- 4.3.1. Abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
- 4.4. Breyanzi (lisocabtagene maraleucel)
- 4.4.1. Breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
- 4.5. Carvykti (ciltacabtagene autoleucel)
- 4.5.1. Carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
- 4.6. Kymriah (tisagenlecleucel)
- 4.6.1. Kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
- 4.7. Tecartus (brexucabtagene autoleucel)
- 4.7.1. Tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
- 4.8. Yescarta (axicabtagene ciloleucel)
- 4.8.1. Yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
- 4.9. Others
- 4.9.1. Others market, 2021 - 2033 (USD Million)
- Chapter 5. Disease Indication Business Analysis
- 5.1. Disease Indication Segment Dashboard
- 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
- 5.3. Leukemia
- 5.3.1. Leukemia market, 2021 - 2033 (USD Million)
- 5.4. Lymphoma
- 5.4.1. Lymphoma market, 2021 - 2033 (USD Million)
- 5.5. Multiple Myeloma
- 5.5.1. Multiple myeloma market, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. Others market, 2021 - 2033 (USD Million)
- Chapter 6. End Use Business Analysis
- 6.1. End Use Segment Dashboard
- 6.2. CAR T-cell Therapy Market: End Use Movement Analysis
- 6.3. Hospitals
- 6.3.1. Hospitals market, 2021 - 2033 (USD Million)
- 6.4. Cancer treatment centers
- 6.4.1. Cancer treatment centers market, 2021 - 2033 (USD Million)
- Chapter 7. Regional Business Analysis
- 7.1. CAR T-cell Therapy Market Share By Region, 2025 & 2033
- 7.2. North America
- 7.2.1. North America CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Competitive Scenario
- 7.2.2.3. Regulatory Framework
- 7.2.2.4. U.S. CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Competitive Scenario
- 7.2.3.3. Regulatory Framework
- 7.2.3.4. Canada CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.3.2. UK
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. UK CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Germany CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Japan CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. China CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- 7.5. Rest of World
- 7.5.1. Rest of World CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Position Analysis, 2025
- 8.4. Company Profiles/Listing
- 8.4.1. Bristol-Myers Squibb Company
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Novartis AG
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Gilead Sciences, Inc.
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Johnson & Johnson Services, Inc.
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. bluebird bio, Inc.
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Merck & Co., Inc.
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Sangamo Therapeutics
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Sorrento Therapeutics, Inc.
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. GSK plc.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
